https://scholars.lib.ntu.edu.tw/handle/123456789/582244
標題: | Mutations in the NS5A and E2-PePHD regions of hepatitis C virus genotype 1b and response to combination therapy of interferon plus ribavirin | 作者: | Yang S.-S. Lai M.-Y. DING-SHINN CHEN Chen G.-H. JIA-HORNG KAO |
關鍵字: | Genetic heterogeneity; Genotype; Hepatitis C virus; Interferon; Ribavirin; Sustained virological response | 公開日期: | 2003 | 出版社: | Blackwell Publishing Ltd | 卷: | 23 | 期: | 6 | 起(迄)頁: | 426-433 | 來源出版物: | Liver International | 摘要: | Background/aims: Combination therapy with interferon (IFN) and ribavirin is the current standard treatment for chronic hepatitis C, but the efficacy is still not satisfactory, especially for genotype 1b. NS5A and E2 proteins of hepatitis C virus (HCV) may repress the IFN-induced RNA-dependent protein kinase (PKR), and thus have the potential to influence the response of HCV to IFN therapy; however, this issue remains controversial. Methods: Nucleotide sequences of the PKR-eIF2α phosphorylation homology domain (E2-PePHD) and PKR-binding domain (NS5A-PKR bd) of the HCV genome were analyzed by amplification and direct sequencing in 30 HCV genotype 1b patients who had been treated with IFN and ribavirin. Results: Nine (30%) patients achieved a sustained virological response (SVR) to combination therapy. Pretreatment variables and amino acid substitutions were compared between responders and non-responders. The responders were younger than non-responders (37.2±10.4 vs. 45.4±9.5 years, P = 0.017), whereas no significant statistical differences were found in the number of amino acid substitutions in NS5A and E2-PePHD regions between the two groups. Conclusions: Genetic heterogeneity in NS5A and E2-PePHD regions of the HCV genome may not serve as a predictor for treatment outcome with combination therapy in Taiwanese patients with chronic HCV genotype 1b infection. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-0346121528&doi=10.1111%2fj.1478-3231.2003.00875.x&partnerID=40&md5=f3f150b418cc24a6084d5c4fc35f0099 https://scholars.lib.ntu.edu.tw/handle/123456789/582244 |
ISSN: | 1478-3223 | DOI: | 10.1111/j.1478-3231.2003.00875.x | SDG/關鍵字: | consensus interferon; peginterferon alpha2b; protein kinase; recombinant alpha2b interferon; ribavirin; RNA; virus protein; adult; age; amino acid substitution; article; clinical article; controlled study; drug efficacy; drug response; female; gene amplification; gene mutation; gene sequence; genetic analysis; genetic heterogeneity; genotype; hepatitis C; Hepatitis C virus; human; male; nonhuman; nucleotide sequence; prediction; protein binding; protein domain; protein phosphorylation; sequence homology; Taiwan; treatment outcome |
顯示於: | 臨床醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。